Research and development
Our ambitious programmes aim to substantially reduce global epidemic and pandemic risk. CEPI’s priority diseases include Chikungunya, COVID-19, Ebola, Lassa Fever, MERS, Mpox, Nipah, Rift Valley Fever, and novel viral threats with epidemic or pandemic potential (also known as “Disease X”).
Enabling science
From biological standards to preclinical models, CEPI supports enabling science activities to accelerate the development of safe and effective vaccines.
Vaccine technology
Vaccines are our most potent weapon against infectious diseases and are at the heart of global responses to epidemic and pandemic threats.
Manufacturing and supply chain
CEPI is bolstering global manufacturing capacity in underserved regions and harnessing innovative technologies to improve the speed, scale and access of vaccine manufacturing in response to epidemic and pandemic threats.
Our portfolio
Our interactive portfolio provides information on each of the vaccine candidates and other projects that CEPI has invested in.
Biosecurity
CEPI’s inaugural Biosecurity Strategy—supported by funding from Global Affairs Canada—aims to bolster global health security, underscoring its commitment to tackling emerging epidemic and pandemic threats, whether they arise naturally, accidentally or through deliberate misuse.
Call for Proposals
We invite innovators worldwide to apply to our scientific programmes to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.
Apply now
Latest News
New funding for vaccine to protect against deadly MERS coronavirus
How disease survivors’ antibodies shape lifesaving vaccines
CEPI and AstraZeneca to advance discovery into novel antibody to help prevent infection during outbreaks
